Research article · 17 Jul 2026
Conference abstractPublished 12 Nov 2013
Supplier management - Key components of managing suppliers in a cGMP environment
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
FDA holds pharmaceutical companies liable for introducing or causing the introduction into interstate commerce of adulterated or misbranded products. FDA Safety and Innovation Act explains that GMPs include owner?s ?implementation of oversight and controls over the manufacture of drugs to ensure quality, including managing the risk of and establishing the safety of raw materials used in the manufacturing of drugs, and finished drug products.? Additionally, new draft guidance on quality agreements, describes the responsibilities of drug manufacturers with respect to oversight of their suppliers. The seminar is a discussion of supplier management covering topics such as vendor qualification, supplier assessment, quality audits, supplier performance, and quality agreements.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Developing Drugs.
Commentary · 4 Feb 2026
Vaccine Development and Global Disease Prevention
Commentary · 4 Feb 2026
Transforming Drug Development Through Pharmaceutical Biotechnology
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Developing Drugs
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Pejman Parhami”
